Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer

NCT03727867 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

DRUG: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
DEVICE: Stereotactic Body Radiation Therapy

Sponsor

Haihua Yang